Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis

Overview

Journal Vaccines (Basel)

Date 2023 Dec 23

PMID 38140206

Authors

Rizky Andhika

Muhammad Iqbal Anand

Marita Restie Tiara

Josephine Debora

Hofiya Djauhari

Evan Susandi

Adnes Mareta

Asep Riswoko

Nopi Susilawati

Agnes Rengga Indrati

Bachti Alisjahbana

Rudi Supriyadi

Affiliations

Soon will be listed here.

Abstract

Patients with end-stage kidney disease on hemodialysis (ESKD-HD) have a high risk of contracting severe COVID-19. Vaccination can help reduce disease severity, but the immune dysregulation observed in these patients may result in an inadequate antibody response. Therefore, we aimed to evaluate the immune response postvaccination in ESKD-HD patients. This prospective cohort study was conducted in two hemodialysis centers in Indonesia. We enrolled ESKD-HD patients ( = 143) pre- and postvaccination and compared them to healthy subjects ( = 67). SARS-CoV-2 antibody response was assessed using anti-S-RBD antibodies and SVNT % inhibition tests. We performed bivariate and multivariate analysis to determine factors associated with SARS-CoV-2 antibody levels. Seropositive conversion was observed in 97% ESKD-HD subjects postvaccination. Compared with healthy subjects, ESKD-HD patients showed a comparable anti-S-RBD antibody titer postvaccination. mRNA vaccines remained a significant factor for the high immune response, while hypoalbuminemia correlated with lower immune response. In conclusion, ESKD-HD patients showed a robust immune response postvaccination. mRNA vaccines induced a stronger antibody response than other vaccines. Lower levels of serum albumin correlate with lower immune responses in ESKD-HD patients after vaccination.

References

Andhika R, Makmun A, Hartantri Y, Wijaya I, Huang I . Challenge in diagnosis of COVID-19 in hemodialysis patient: a case report and brief review of the literature. CEN Case Rep. 2021; 10(3):341-347. PMC: 7810596. DOI: 10.1007/s13730-020-00571-w. View

Kwiatkowska E, Safranow K, Wojciechowska-Koszko I, Roszkowska P, Dziedziejko V, Myslak M . SARS-CoV-2 mRNA Vaccine-Induced Cellular and Humoral Immunity in Hemodialysis Patients. Biomedicines. 2022; 10(3). PMC: 8945424. DOI: 10.3390/biomedicines10030636. View

Sanhueza M, San Martin P, Brantes L, Caro S, Carrasco G, Machuca E . Efficacy of vaccination against the SARS-CoV-2 virus in patients with chronic kidney disease on hemodialysis. Hum Vaccin Immunother. 2023; 19(1):2173904. PMC: 10012891. DOI: 10.1080/21645515.2023.2173904. View

Karoui K, De Vriese A . COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. Kidney Int. 2022; 101(5):883-894. PMC: 8842412. DOI: 10.1016/j.kint.2022.01.022. View

Agur T, Ben-Dor N, Goldman S, Lichtenberg S, Herman-Edelstein M, Yahav D . Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospectivecohort study. Nephrol Dial Transplant. 2021; . PMC: 8083335. DOI: 10.1093/ndt/gfab155. View

Lim J, Hang S, Hariharaputran S, Chia A, Tan N, Lee E . A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines. Cell Rep Med. 2022; 3(11):100793. PMC: 9534788. DOI: 10.1016/j.xcrm.2022.100793. View

Ward E, Gelinas D, Dreesen E, Van Santbergen J, Andersen J, Silvestri N . Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders. Front Immunol. 2022; 13:892534. PMC: 9231186. DOI: 10.3389/fimmu.2022.892534. View

Dheir H, Tocoglu A, Toptan H, Pinar M, Demirci T, Koroglu M . Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients. J Med Virol. 2022; 94(7):3176-3183. PMC: 9088488. DOI: 10.1002/jmv.27714. View

Castrejon-Jimenez N, Garcia-Perez B, Reyes-Rodriguez N, Vega-Sanchez V, Martinez-Juarez V, Hernandez-Gonzalez J . Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis. Biosensors (Basel). 2022; 12(9). PMC: 9496238. DOI: 10.3390/bios12090728. View

10.

Alcazar-Arroyo R, Portoles J, Lopez-Sanchez P, Zalamea F, Furaz K, Mendez A . Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study. Clin Kidney J. 2021; 14(7):1835-1844. PMC: 7989535. DOI: 10.1093/ckj/sfab048. View

11.

Hirai K, Shimotashiro M, Sonoda T, Okumura T, Ookawara S, Morishita Y . Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients. Clin Exp Nephrol. 2022; 26(9):925-932. PMC: 9012063. DOI: 10.1007/s10157-022-02223-y. View

12.

Broseta J, Rodriguez-Espinosa D, Rodriguez N, Mosquera M, Marcos M, Egri N . Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. Am J Kidney Dis. 2021; 78(4):571-581. PMC: 8223037. DOI: 10.1053/j.ajkd.2021.06.002. View

13.

Keller U . Nutritional Laboratory Markers in Malnutrition. J Clin Med. 2019; 8(6). PMC: 6616535. DOI: 10.3390/jcm8060775. View

14.

Tiara M, Djauhari H, Rachman F, Rettob A, Utami D, Pulungan F . Performance of a Point-of-Care Fluorescence Immunoassay Test to Measure the Anti-Severe Acute Respiratory Syndrome Corona Virus 2 Spike, Receptor Binding Domain Antibody Level. Diagnostics (Basel). 2023; 13(24). PMC: 10743294. DOI: 10.3390/diagnostics13243686. View

15.

Gleeson M, Dickson R . Albumin gains immune boosting credibility. Clin Transl Gastroenterol. 2015; 6:e86. PMC: 5176317. DOI: 10.1038/ctg.2015.11. View

16.

Shurrab F, Younes N, Al-Sadeq D, Liu N, Qotba H, Abu-Raddad L . Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals. Int J Infect Dis. 2022; 118:132-137. PMC: 8882034. DOI: 10.1016/j.ijid.2022.02.052. View

17.

Clavero R, Parra-Lucares A, Mendez-Valdes G, Villa E, Bravo K, Mondaca E . Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort. Vaccines (Basel). 2022; 10(9). PMC: 9503801. DOI: 10.3390/vaccines10091542. View

18.

van Praet J, Reynders M, De Bacquer D, Viaene L, Schoutteten M, Caluwe R . Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. J Am Soc Nephrol. 2021; 32(12):3208-3220. PMC: 8638385. DOI: 10.1681/ASN.2021070908. View

19.

Puspitasari M, Sattwika P, Rahari D, Wijaya W, Hidayat A, Kertia N . Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in haemodialysis patients: a prospective cohort study. Sci Rep. 2023; 13(1):11557. PMC: 10354113. DOI: 10.1038/s41598-023-38628-2. View

20.

Puspitasari M, Sattwika P, Rahari D, Wijaya W, Hidayat A, Kertia N . Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: A systematic review and meta-analysis. PLoS One. 2023; 18(2):e0281160. PMC: 9910685. DOI: 10.1371/journal.pone.0281160. View